Clinical trials: psoriasis
Plaque Psoriasis
Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)
This is a randomized, double-blind, vehicle-controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in adults.
- Trial name
- NCT03956355
- Testing
- Tapinarof, Vehicle Cream
- Where
- 53 sites in United States, Canada
- Volunteers
- 510 people
- Sponsor
- Organon and Co
Parapsoriasis
A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.
This study will evaluate the clinical efficacy, the patients quality of life, and safety of oral apremilast 30 mg twice daily (BID) compared to placebo, in adult patients with moderate plaque psoriasis during the 16 week Placebo…
- Trial name
- UNVEIL (NCT02425826)
- Testing
- Apremilast
- Where
- 26 sites in United States
- Volunteers
- 221 people
- Sponsor
- Amgen
Plaque-type Psoriasis
Study of Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis
Low doses of topically administered vitamin D analogs have been shown to have an anti-psoriatic effect without the risk of hypercalcemia.
- Trial name
- NCT00625326
- Testing
- COL-121, 50 µg/g Calcipotriene Ointment
- Where
- 20 sites in United States
- Volunteers
- 321 people
- Sponsor
- Deltanoid Pharmaceuticals
Psoriasis
Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects
Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the treatment of psoriasis. There were 3 dose cohorts (75mg, 90mg, 105mg) with 12 healthy subjects in each cohorts (6 males and 6 females).
- Trial name
- Hemay005 (NCT04837235)
- Testing
- Hemay005
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
Psoriasis
Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects
It is a randomized, double-blinded, single-dose, 3-arm parallel, comparative study to evaluate the pharmacokinetics, safety and immunogenicity of BAT2306 Injection vs Cosentyx® (EU-licensed and US-licensed) in healthy Chinese…
- Trial name
- NCT04711343
- Testing
- BAT2306, Cosentyx (US-licensed), Cosentyx (EU-licensed)
- Where
- China
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Bio-Thera Solutions
Plaque Psoriasis
Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis
This Phase 2 study has been designed to determine and compare the safety, tolerability, and efficacy of DUR-928 topical solution with that of the vehicle topical solution when applied once daily for approximately four weeks in…
- Trial name
- NCT03837743
- Testing
- DUR-928 Topical Solution, Vehicle Topical Solution
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Durect
Plaque Psoriasis
Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%
The aim of this study is to investigate the utility of a technological based rating scale for assessing improvement in plaque psoriasis with Clobex spray treatment.
- Trial name
- NCT01893567
- Testing
- Clobex Spray
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Galderma R&D
Psoriatic Arthritis
Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis
This study is designed as an extension study to the proof-of-concept trial CAIN457A2206 in patients with psoriatic arthritis and aims to provide continuous treatment with AIN457 for patients in the core trial, to obtain safety…
- Trial name
- NCT01169844
- Testing
- AIN457A, Other
- Where
- 6 sites in Germany, Netherlands and 1 more
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Plaque Psoriasis
Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis
The aim of the study is to evaluate the efficacy and safety of netakimab compared with placebo in a pediatric population of subjects over 6 years of age with moderate to severe plaque psoriasis.
- Trial name
- PLANETA-KIDS (NCT06640517)
- Testing
- Netakimab, Adalimumab
- Where
- 14 sites in Russia
- Volunteers
- 140 people
- Sponsor
- Biocad
Psoriasis
Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis
The primary objective of this study is to compare the effects on disease activity, in the absence of systemic psoriasis therapy, of 4 mg/kg MEDI-522 versus placebo administered weekly by SC injection for 12 weeks.
- Trial name
- NCT00192517
- Testing
- MEDI-522
- Where
- 20 sites in United States, Canada
- Volunteers
- 44 people
- Sponsor
- MedImmune LLC
Psoriasis
Post-Marketing Surveillance Study of OTEZLA
To evaluate the safety and efficacy of OTEZLA in actual clinical settings of use in patients with Psoriasis vulgaris that is with an inadequate response to topical therapies and Psoriasis arthropathica 1.
- Trial name
- NCT03284879
- Where
- Japan
- Volunteers
- 1,086 people
- Sponsor
- Amgen
Psoriasis
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
REALIZE study will include a representative sample of 500 patients with moderate to severe plaque psoriasis for whom the treating dermatologist has decided to begin apremilast treatment in accordance with the local label…
- Trial name
- REALIZE (NCT03757013)
- Testing
- Apremilast
- Where
- 93 sites in France
- Volunteers
- 453 people
- Sponsor
- Amgen
Plaque Psoriasis
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis
This is a Phase 2, multicenter, randomized, double-blinded, parallel dose group, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of 2 doses of TLL018 as therapy in approximately 90 participants with…
- Trial name
- NCT05772520
- Testing
- TLL018 tablets
- Where
- 35 sites in United States
- Volunteers
- 82 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Psoriasis
A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
The purpose of the study is to evaluate pharmacokinetic similarity, efficacy, safety and immunogenicity of multiple switches between ustekinumab and ABP 654 compared with continued use of ustekinumab in participants with moderate…
- Trial name
- NCT04761627
- Testing
- Ustekinumab, ABP 654
- Where
- 88 sites in United States, Canada and 6 more
- Volunteers
- 494 people
- Sponsor
- Amgen
Plaque Psoriasis
Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis
The objective of this study is to evaluate the potential of Topicort® (desoximetasone) Topical Spray, 0.25% to suppress hypothalmic pituitary adrenal axis function.
- Trial name
- NCT02340169
- Testing
- Topicort® (desoximetasone) Topical Spray, 0.25%
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis
A Study for Adults With Plaque Psoriasis
In this study, we will evaluate clinical activity, safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of 5 LY2525623 dosing groups compared to placebo in adults with plaque psoriasis.
- Trial name
- NCT01018810
- Testing
- LY2525623 Intravenous, LY2525623 Subcutaneous
- Where
- 28 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- Eli Lilly and Company
Scalp Psoriasis
Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis
A Randomized Double-Blind, Vehicle-Controlled, Parallel Design, Multiple-Site, Phase III Clinical Study
- Trial name
- NCT02932462
- Testing
- DSXS
- Volunteers
- 373 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Plaque Psoriasis
A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis
The primary objective of this study is to evaluate the efficacy of apremilast in children and adolescents (ages 6 through 17 years) with moderate to severe plaque psoriasis.
- Trial name
- NCT05565560
- Testing
- Apremilast
- Where
- 29 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Amgen
Psoriasis
IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
The purpose of this study is to evaluate the efficacy, safety, and tolerability of IBI112 in the treatment of participants with moderate to severe psoriasis
- Trial name
- NCT06049810
- Testing
- IBI112
- Where
- China
- Volunteers
- 566 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.